| scholarly article | Q13442814 |
| P2093 | author name string | Collen D | |
| Colucci M | |||
| Paramo JA | |||
| van de Werf F | |||
| P2860 | cites work | Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation | Q34535595 |
| Mechanisms of inhibition of tissue-type plasminogen activator in blood | Q70457180 | ||
| Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions | Q70477525 | ||
| Fibrinolytic activity and coronary-artery disease | Q93738355 | ||
| P433 | issue | 6495 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | coronary artery disease | Q844935 |
| plasminogen | Q107129060 | ||
| P1104 | number of pages | 2 | |
| P304 | page(s) | 573-574 | |
| P577 | publication date | 1985-08-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Plasminogen activator inhibitor in the blood of patients with coronary artery disease | |
| P478 | volume | 291 |
| Q93081974 | A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements |
| Q37202358 | A critical review of the relationship between impaired fibrinolysis and myocardial infarction |
| Q50981804 | A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. |
| Q57306796 | Alcohol consumption and plasminogen activator inhibitor type 1: The national heart, lung, and blood Institute family heart study |
| Q61700582 | Changes in the Fibrinolytic System in Patients with Peripheral Arterial Occlusive Disease Undergoing Percutaneous Transluminal Angioplasty |
| Q41916813 | Changes in the fibrinolytic system associated with physical conditioning |
| Q37054785 | Circadian Variation of Fibrinolytic Activity in Blood |
| Q42577762 | Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. |
| Q38255357 | Clinical disorders of fibrinolysis: a critical review |
| Q69368701 | Desmopressin and myocardial infarction |
| Q33860684 | Dietary supplementation with highly purified eicosapentaenoic acid and docosahexaenoic acid does not influence PAI-1 activity |
| Q67900163 | Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol |
| Q72897752 | Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction |
| Q36197578 | Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea. |
| Q71808013 | Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a) |
| Q42494570 | Features of endothelial dysfunction in early diabetic nephropathy |
| Q35224492 | Fibrin and Its Derivatives in the Normal and Diseased Vessel Wall |
| Q40492595 | Fibrinogen in Human Atherosclerosis |
| Q71126187 | Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients |
| Q40582633 | Fibrinolysis and thrombosis |
| Q73681245 | Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease |
| Q40582647 | Genetic determinants of arterial thrombosis |
| Q41047291 | Hemostatic factors as triggers of cardiovascular events. |
| Q72610140 | High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction |
| Q37786770 | Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease |
| Q70500152 | Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction |
| Q69625983 | Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol |
| Q37374639 | Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis |
| Q37131350 | Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries |
| Q40812885 | Insulin resistance and risk factors for coronary heart disease |
| Q67678146 | Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium |
| Q62694077 | Markers of fibrinolytic potency and clotting activation in stable angina pectoris: role of urokinase, assessment of atrioventricular differences and correlation with coronary patency |
| Q73438239 | Markers of risk in young offspring with paternal history of myocardial infarction |
| Q37864466 | Mechanism of action of the thrombolytic agents |
| Q38488614 | Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study |
| Q39591872 | Pharmacology of thrombolytic drugs |
| Q40737304 | Physical activity and lipoprotein lipid disorders |
| Q41047260 | Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events |
| Q70322551 | Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations |
| Q33664574 | Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? |
| Q72049373 | Plasminogen Activator System in Human Coronary Atherosclerosis |
| Q34117320 | Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34376916 | Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. |
| Q40305997 | Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis |
| Q73589915 | Plasminogen activator inhibitor-1, the acute phase response and vitamin C |
| Q73295825 | Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors |
| Q34205401 | Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta |
| Q74251504 | Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction |
| Q67655854 | Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies |
| Q67687946 | The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a) |
| Q34421664 | The mechanisms of thrombotic risk induced by hormone replacement therapy |
| Q35477781 | The plasminogen-plasmin system in malignancy |
| Q42979228 | Thrombin and plasmin activity in coronary artery disease |
| Q64239248 | Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease |
| Q38236911 | Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent |
| Q36721982 | Vessel Wall-Related Risk Factors in Acute Vascular Events |
| Q67244732 | [Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct] |
Search more.